BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Regulation FD Disclosure
Item 7.01
BeiGene,Ltd. (the “Company”) will be meeting with investors at the 37th Annual J.P. Morgan Healthcare Conference during the week of January6, 2019 in San Francisco (the “J.P. Morgan Conference”). A copy of the Company’s presentation to be shared with investors at the J.P. Morgan Conference is attached as Exhibit99.1 to this Current Report on Form8-K and is incorporated by reference herein. The presentation shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section11 and 12(a)(2)of the Securities Act of 1933, as amended.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| ExhibitNo. | Description |
| 99.1 | BeiGene,Ltd. presentation dated January6, 2019 |
ExhibitIndex
BeiGene, Ltd. Exhibit
EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation January 6,…
To view the full exhibit click here
About BEIGENE,LTD. (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.